# Re-evaluation Task: HN2-018

## Context
- **Case ID**: HN2-018
- **Cancer type**: Laryngeal Large Cell Neuroendocrine Carcinoma (LCNEC)
- **Stage**: T3N1M0 (Stage III)
- **Molecular profile**: Synaptophysin positive, Chromogranin A positive, Ki-67 70%, RB1 loss, PD-L1 CPS 10, Poorly differentiated neuroendocrine carcinoma
- **Report file**: experiment_reports\HN2-018_report.json
- **Current score**: 86/100
- **Gap analysis (local GPU)**: The lack of data on Irinotecan/Cisplatin (IP Regimen) and Pembrolizumab Monotherapy (Anti-PD-1) regimens will hinder the ability to assess their efficacy in treating head and neck cancer, which is a critical gap as these treatments are commonly used in this patient population. Filling these gaps with high-quality data will improve the score by providing a more comprehensive understanding of treatment options for patients with head and neck cancer, ultimately informing more effective treatment strategies.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| evidence_depth                      |  13/25  |  52.0% |
| clinical_relevance                  |   9/10  |  90.0% |
| rating_calibration                  |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |
| source_quality                      |  15/15  | 100.0% |
| combo_supportive_coverage           |  10/10  | 100.0% |

## Target dimension: `evidence_depth` (52.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN2-018_report.json`.

Your task: Fill missing evidence fields in `treatments[].key_evidence`.

For each treatment where these are null or missing, search and fill:
- `key_evidence.study_name` — full trial name
- `key_evidence.year` — publication year
- `key_evidence.sample_size` — numeric patient count
- `key_evidence.os_months.treatment` — median OS in treatment arm (months)
- `key_evidence.os_months.control` — median OS in control arm (months)
- `key_evidence.os_months.hazard_ratio` — HR from primary analysis
- `key_evidence.os_months.p_value` — p-value from OS analysis
- `key_evidence.pfs_months.treatment` — median PFS treatment arm
- `key_evidence.pfs_months.control` — median PFS control arm

Rules:
- Only fill with data you can verify from published trials
- Set to null (not omit) if genuinely unavailable after searching
- Do NOT fabricate or estimate numbers

Return the corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Laryngeal Large Cell Neuroendocrine Carcinoma (LCNEC)",
    "stage": "T3N1M0 (Stage III)",
    "molecular_profile": [
      "Synaptophysin positive",
      "Chromogranin A positive",
      "Ki-67 70%",
      "RB1 loss",
      "PD-L1 CPS 10",
      "Poorly differentiated neuroendocrine carcinoma"
    ],
    "patient_demographics": {
      "age": 45,
      "sex": "Male",
      "smoking_status": "Active smoker",
      "relevant_history": "Smoking history contributes to neuroendocrine carcinoma risk in the larynx"
    }
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Carboplatin/Etoposide + Atezolizumab (IMpower133 Regimen)",
      "category": "Immunotherapy Combination",
      "composite_rating": 7.1,
      "rating_breakdown": {
        "evidence_level": {
          "score": 7,
          "rationale": "Phase 3 IMpower133 trial established carboplatin-etoposide-atezolizumab as standard first-line for ES-SCLC (HR 0.70 for OS, p=0.007). Extrapolation to LCNEC with RB1 loss (SCLC-like molecular subtype) is biologically rational. No prospective data specifically in laryngeal LCNEC. PD-L1 CPS 10 provides additional rationale for checkpoint blockade."
        },
        "survival_benefit": {
          "score": 7,
          "rationale": "IMpower133: median OS 12.3 months vs 10.3 months (HR 0.70). 5-year OS rate 12% vs 2.6%. Benefit seen independent of PD-L1 status. For RB1-loss LCNEC, SCLC-like biology predicts similar sensitivity. PD-L1 CPS 10 may confer additional benefit from atezolizumab component."
        },
        "accessibility": {
          "score": 7,
          "rationale": "Atezolizumab is FDA-approved for ES-SCLC but not specifically for extrapulmonary LCNEC. Off-label use may be supported by tumor board discussion and institutional policies. Carboplatin-etoposide backbone is universally accessible."
        },
        "safety_profile": {
          "score": 6,
          "rationale": "Safety profile consistent with individual agents. Immune-related adverse events (pneumonitis, hepatitis, thyroiditis) in 10-15%. Grade 3-4 neutropenia common. Manageable with appropriate monitoring and steroid protocols."
        },
        "biomarker_match": {
          "score": 9,
          "rationale": "RB1 loss defines SCLC-like molecular subtype of LCNEC, directly supporting use of the SCLC standard-of-care regimen. PD-L1 CPS 10 provides further rationale for checkpoint inhibitor inclusion. IMpower133 showed benefit regardless of PD-L1 status."
        }
      },
      "mechanism_of_action": "Carboplatin-etoposide provides cytotoxic backbone targeting rapidly dividing neuroendocrine cells. Atezolizumab (anti-PD-L1) blocks the PD-1/PD-L1 checkpoint, reactivating T-cell-mediated antitumor immunity. Chemotherapy-induced immunogenic cell death may enhance immune checkpoint blockade efficacy. PD-L1 CPS 10 suggests the tumor microenvironment may be susceptible to immune reac
... (truncated — read full file from experiment_reports\HN2-018_report.json)
```
